Hims & Hers Adds Novo Nordisk GLP-1 Treatments
Krissy Vann | Host, All Things Fitness and Wellness
Hims & Hers Health has announced expanded access to a range of GLP-1 medications through a new collaboration with Novo Nordisk, making several FDA-approved treatments available to eligible customers through its platform.
The offering includes multiple forms and dosages of semaglutide-based medications, including Wegovy and Ozempic. According to the company, this includes both injectable and oral formats, with pricing starting at $149 per month depending on the treatment and clinical eligibility.
Access to these medications is determined by independent healthcare providers. Eligible users may be prescribed GLP-1 treatments as part of a broader weight management plan, with some options positioned to support weight loss outcomes of up to 20 percent, based on clinical data referenced by the company.
Ozempic, which is approved for the treatment of type 2 diabetes, may also be prescribed based on individual clinical judgment. It is not approved by the FDA for weight loss.
Alongside medication access, Hims & Hers is introducing a weight loss membership program that includes ongoing provider access, nutrition guidance, clinical check-ins, and community-based support. The membership is priced at $39 for the first month and $149 per month thereafter, with medication costs billed separately. The company notes that some costs may be eligible for reimbursement through HSA or FSA plans.
The expanded offering also includes the option for compounded GLP-1 medications in cases where a provider determines that commercially available treatments do not meet a patient’s clinical needs.
This move increases the range of prescription weight management options available through the Hims & Hers platform, which operates as a direct-to-consumer telehealth service.
